Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
6 pending office actions • 4 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Metriopharm AG currently has 6 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 6 distinct examiners, meaning that every pending matter is being reviewed by a different individual. This distribution requires a prosecution strategy that accounts for the specific tendencies of each examiner rather than a centralized approach.
The portfolio is spread across 4 distinct art units within the patent office. Having these filings in 4 art units suggests that some technical overlap exists, yet the majority of the work is handled by different administrative groups. Practitioners should coordinate their arguments to ensure consistency across these distinct groups while addressing the specific technical requirements of the Biotechnology & Pharmaceuticals sector.
SHIAO, REI TSANG is the busiest examiner for this company, with 1 pending office action currently assigned. Since the busiest examiner holds only 1 of the 6 total actions, the workload is evenly distributed across the examiner pool. This lack of concentration means that no single examiner has a dominant influence over the company's current patent applications.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (17%) |
| Double-patenting + other | 2 (33%) |
| Multi-statute (no §101) | 3 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHIAO, REI TSANG | 1 | 79.8% | -33.6% |
| GONZALEZ, LUISALBERTO | 1 | 59.4% | +47.2% |
| NESTOR, DONNA MICHELLE | 1 | 56.6% | +44.2% |
| BAUER, NICOLA MARIA | 1 | 58.3% | +50.0% |
| LEE, ANDREW P | 1 | 48.3% | +23.1% |
| PHILIPS, BRADLEY H | 1 | 67.4% | +30.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18001034 | COMPOUND FOR THE TREATMENT OF CORONAVIRAL INFECTIONS | BAUER, NICOLA MARIA | 88d overdue |
| 18726854 | COMBINATION OF BUDESONIDE AND 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE | GONZALEZ, LUISALBERTO | — |
| 17795360 | USE OF 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE IN THE INHALATORY TREATMENT OF INFLAMMATORY PULMONARY DISEASES | PHILIPS, BRADLEY H | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18001034 | COMPOUND FOR THE TREATMENT OF CORONAVIRAL INFECTIONS | BAUER, NICOLA MARIA | 88d overdue |
| 18255262 | LUMINOL FOR THE PROPHYLAXIS AND THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | NESTOR, DONNA MICHELLE | 42d overdue |
| 18726854 | COMBINATION OF BUDESONIDE AND 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE | GONZALEZ, LUISALBERTO | — |
| 17913687 | 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE FOR TREATMENT OF ACUTE LUNG INJURY | LEE, ANDREW P | — |
| 17795360 | USE OF 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE IN THE INHALATORY TREATMENT OF INFLAMMATORY PULMONARY DISEASES | PHILIPS, BRADLEY H | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| 1621 | 1 |
| 1691 | 1 |
| 3799 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18850379 | COMBINATION OF 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE AND A FUMARIC ACID ESTER | SHIAO, REI TSANG | — | §103§112DP | Non-Final OA | — | Pending | Sep 24, 2024 |
| 18726854 | COMBINATION OF BUDESONIDE AND 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE | GONZALEZ, LUISALBERTO | — | §103§112Other | Non-Final OA | — | Pending | Jul 05, 2024 |
| 18255262 | LUMINOL FOR THE PROPHYLAXIS AND THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | NESTOR, DONNA MICHELLE | 1627 | §103DP | Non-Final OA | 42d overdue | Pending | May 31, 2023 |
| 18001034 | COMPOUND FOR THE TREATMENT OF CORONAVIRAL INFECTIONS | BAUER, NICOLA MARIA | 1621 | §103§112 | Final Rejection | 88d overdue | Pending | Dec 07, 2022 |
| 17913687 | 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE FOR TREATMENT OF ACUTE LUNG INJURY | LEE, ANDREW P | 1691 | §103 | Final Rejection | — | Pending | Sep 22, 2022 |
| 17795360 | USE OF 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE IN THE INHALATORY TREATMENT OF INFLAMMATORY PULMONARY DISEASES | PHILIPS, BRADLEY H | 3799 | §103§112 | Non-Final OA | — | Pending | Jul 26, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial